LY3537031 + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Alcohol Use Disorder
Conditions
Alcohol Use Disorder
Trial Timeline
Oct 16, 2025 → Apr 1, 2028
NCT ID
NCT07219953About LY3537031 + Placebo
LY3537031 + Placebo is a phase 3 stage product being developed by Eli Lilly for Alcohol Use Disorder. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07219953. Target conditions include Alcohol Use Disorder.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07219953 | Phase 3 | Recruiting |
| NCT07219966 | Phase 3 | Recruiting |
| NCT06606106 | Phase 1 | Active |
| NCT04648865 | Phase 1 | Completed |
Competing Products
20 competing products in Alcohol Use Disorder
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK2809 + Placebos | Viking Therapeutics | Phase 2 | 47 |
| TERN-501 + TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-101 | Terns Pharmaceuticals | Phase 2 | 49 |
| TERN-201 | Terns Pharmaceuticals | Phase 1 | 30 |
| IVA337 + IVA337 + Placebo | Inventiva | Phase 2 | 47 |
| Lanifibranor | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo + Empagliflozin | Inventiva | Phase 2 | 47 |
| IVA337 + Placebo | Inventiva | Phase 3 | 72 |
| LY686017 + Placebo | Eli Lilly | Phase 2 | 52 |
| AD04 (ondansetron) + Matching placebo | Adial Pharmaceuticals | Phase 3 | 69 |
| GODEX + Placebo | Celltrion | Phase 3 | 77 |
| Colesevelam Hcl | Daiichi Sankyo | Phase 2 | 52 |
| ASP9831 + Placebo | Astellas Pharma | Phase 2 | 52 |
| ASP8062 + Placebo | Astellas Pharma | Phase 2 | 52 |
| LY686017 + Placebo | Eli Lilly | Phase 2 | 52 |
| Mazdutide + Placebo | Eli Lilly | Phase 2 | 52 |
| opioid receptor kappa antagonist | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Placebo | Eli Lilly | Phase 2 | 52 |
| LY2196044 + placebo | Eli Lilly | Phase 2 | 52 |
| LY3537031 + Placebo | Eli Lilly | Phase 3 | 77 |